Stockscreener 앱 받기
2.46
2.50%
0.06
시간 외 거래:
2.36
-0.10
-4.07%
Ovid Therapeutics Inc 주식(OVID)의 최신 뉴스
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Ovid Therapeutics (NASDAQ: OVID) chair exercises 47,333-share warrant at $1.40 - Stock Titan
Investors pour $60M into Ovid Therapeutics to advance seizure drugs - Crain's New York Business
Ovid Therapeutics secures $60M funding to advance epilepsy drug programs - MSN
Ovid Therapeutics' new epilepsy trial data ignites rally - MSN
If You Invested $1,000 in Ovid Therapeutics Inc (OVID) - Stock Titan
Here's why Ovid Therapeutics stock popped higher today - MSN
Wall Street Zen Upgrades Ovid Therapeutics (NASDAQ:OVID) to Hold - MarketBeat
Ovid Therapeutics Sells Ganaxolone Royalty Rights for $7M to Immedica Pharma - MSN
Ovid Therapeutics Stock Surges on Positive Drug Trial Data and Financing Plans - StocksToTrade
Ovid Shares Surge with Positive Phase 1 Results and Strategic Moves - timothysykes.com
Wedbush Forecasts Strong Price Appreciation for Ovid Therapeutics (NASDAQ:OVID) Stock - MarketBeat
Ovid Therapeutics (OVID) Sees Price Target Raised by Wedbush | O - GuruFocus
Bond Watch: How does Ovid Therapeutics Inc score in quality rankingsMarket Performance Report & Daily Technical Forecast Reports - baoquankhu1.vn
Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding - Seeking Alpha
Here's Why Ovid Therapeutics Stock Popped Higher Today - AOL.com
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target By Investing.com - Investing.com Australia
B.Riley reiterates Buy on Ovid Therapeutics stock, $5 target - Investing.com
Ovid Therapeutics Hits New 52-Week High of $2.50, Marking Major Milestone - Markets Mojo
Leerink reiterates Ovid Therapeutics stock rating on safety data By Investing.com - Investing.com South Africa
Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally - Sahm
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results - Sahm
Leerink reiterates Ovid Therapeutics stock rating on safety data - Investing.com
Ovid Therapeutics advances OV329 epilepsy drug, secures $60M financing - MSN
Ovid’s KCC2 direct activator OV-4071 cleared for clinic - BioWorld MedTech
Ovid Therapeutics (OVID) Q4 earnings and revenues surpass estimates - MSN
Ovid Therapeutics Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:OVID) 2026-03-19 - Seeking Alpha
Ovid Therapeutics Shares Surge After Positive Epilepsy Drug Trial Results - MSN
Ovid Therapeutics raises $60 million to expand drug development By Investing.com - Investing.com South Africa
Ovid Therapeutics raises $60M, expands epilepsy drug development By Investing.com - Investing.com South Africa
Ovid Therapeutics: Advancing Small Molecule Medicines for Epilepsy and Psychiatric Disorders – Pipeline, Strategy, and Company Overview - Minichart
Ovid Therapeutics (OVID) Q4 Profit Challenges Ongoing Loss Narrative - simplywall.st
Earnings Call Summary | Ovid Therapeutics(OVID.US) Q4 2025 Earnings Conference - 富途牛牛
Ovid Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Ovid Therapeutics Q4 Earnings Call Highlights - MarketBeat
Ovid Therapeutics 2025 10-K: $7.3M Revenue, $(17.41)M Net Loss - TradingView
OVID: 2025 saw higher revenue, reduced losses, and strong cash to support advancing CNS drug programs - TradingView
[10-K] Ovid Therapeutics Inc. Files Annual Report | OVID SEC FilingForm 10-K - Stock Titan
Ovid Therapeutics (OVID) Reports Strong Q4 Revenue and Expands C - GuruFocus
Ovid Therapeutics (OVID) Swings to $0.06 EPS in Q4 FY25 - AlphaStreet
Here's Why Ovid Therapeutics Stock Popped Higher Today - The Motley Fool
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Ovid Therapeutics Expands OV329 Epilepsy Program, Launches Phase 1 OV4071 Trial, and Reports Strong 2025 Financial Results - Minichart
Ovid Therapeutics Faces Market Uncertainty Amid Recent Earnings Review - StocksToTrade
Earnings call transcript: Ovid Therapeutics Q4 2025 Surprises with Earnings Beat - Investing.com
OVID’s Latest Strategic Moves Propel Stock Price Surge - timothysykes.com
Ovid Therapeutics earnings beat by $0.17, revenue topped estimates - Investing.com Canada
Ovid Therapeutics Inc. announced that it expects to receive $59.99992 million in funding from a group of investors - marketscreener.com
Ovid Therapeutics (OVID) Q4 Results Exceed Expectations for Earnings and Revenue - Bitget
Ovid (OVID) Reports Strong Cash Position as of Year-End 2025 - GuruFocus
0.04%
0.06%
자본화:
|
볼륨(24시간):